Back to top
more

Clovis Oncology (CLVS)

(Delayed Data from NSDQ)

$1.12 USD

1.12
2,055,496

-0.06 (-5.08%)

Updated Sep 23, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy18.00%
3Hold9.55%
4Sell5.25%
5Strong Sell2.32%
S&P50010.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Trades from $1

Zacks News

Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.

Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know

Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.

Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results

Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.

Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?

Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.

Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study

Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.

Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.